Bioavailability

From open-encyclopedia.com - the free encyclopedia.

In pharmacology, bioavailability is a term used to describe a pharmacokinetic property of drugs, namely, the fraction of a dose which reaches the systemic circulation. It is an essential tool in pharmacokinetics, as bioavailability must be considered when calculating dosages for administration routes other than intravenous.

Definition

Bioavailability is a measurement of the rate and extent of therapeutically active drug that reaches the systemic circulation and is available at the site of action. (Shargel & Yu, 1999)

It is expressed as the letter F.

Absolute bioavailability

Absolute bioavailability measures the availability of the active drug in systemic circulation after non-intravenous administration (i.e. after oral, rectal, transdermal, subcutaneous, etc administration).

In order to determine absolute bioavailability of a drug, a pharmacokinetic study must be done to obtain a plasma drug concentration vs time plot for the drug after both intravenous and extravascular administration. The absolute bioavailability is the dose-corrected area under curve (AUC) extravascular divided by AUC intravenous.

<math>F = \frac{[AUC]_{po}*dose_{IV}}{[AUC]_{IV}*dose_{po}}<math>

Note here that a drug given by the intravenous route will have an absolute bioavailability of 1 (F=1). Drugs given by other routes usually have an absolute bioavailability of less than one.

Relative bioavailability

This measures the bioavailability of the a certain drug when compared with another formulation of the same drug, usually an established standard, or through administration via a different route. When the standard consists of intravenously administered drug, this is known as absolute bioavailability.

<math>\mathit{relative\ bioavailability} = \frac{[AUC]_{A}*dose_{B}}{[AUC]_{B}*dose_{A}}<math>

Factors influencing bioavailability

As mentioned above the absolute bioavailability of a drug, when administered by an extravascular route, is usually less than one. This means that there are factors at work which reduce the availability of the drug prior to it entering the systemic circulation.

Such factors may include, but are not limited to:

• poor absorption from the gastrointestinal tract
• hepatic first-pass effect
• degradation of the drug prior to reaching system circulation

References

• Shargel, L.; Yu, A.B. (1999). Applied biopharmaceutics & pharmacokinetics (4th ed.). New York: McGraw-Hill. ISBN 0-8385-0278-4.

See also

ADME-Tox, Lipinski's Rule of 5

de:Bioverfügbarkeit